Marker Therapeutics, Inc. Common Stock

MRKRNASDAQ • USD
0.90 USD
↗ 0.07 (8.62%)🟢PRE MARKET (AS OF 09:19 AM EST)
🟢Market: OPEN

Marker Therapeutics, Inc. Common Stock (MRKR) is currently trading at $0.90. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 16, 2026.

Open?$0.82
High?$1.00
Low?$0.81
Prev. Close?$0.83
Volume?36.8K
Avg. Volume?166.3K
VWAP?$0.90
Rel. Volume?0.22x
Bid / Ask
Bid?$0.71 × 100
Ask?$1.06 × 100
Spread?$0.35
Midpoint?$0.88
Valuation & Ratios
Market Cap?13.8M
Shares Out?16.7M
Float?12.9M
Float %?77.5%
P/E Ratio?N/A
P/B Ratio?1.14
EPS?-$0.52
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Employees
5
Market Cap
14.5M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
1998-01-07
Address
2450 HOLCOMBE BLVD
HOUSTON, TX 77021
Phone: (713) 400-6400
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
80
Piotroski F-Score?0/9Weak
Altman Z-Score?-42.39Distress
Confidence?43%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.36%Low
Short Interest?176.1K
Days to Cover?1.0
Free Float12.9M
Avg Daily Volume255.5K
Settlement Date2026-10-30
Financial Health
Current Ratio?6.03Strong
Quick Ratio?6.03Strong
Cash Ratio?4.68Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
94
1.14CHEAP▾
P/S?
Peers
100
S&P
23
5.92FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.2CHEAP▾
EV/Sales?
Peers
100
S&P
91
1.07CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-71.6%WEAK▾
ROA?
S&P
3
-59.7%WEAK▾
Cash Flow & Enterprise
FCF?$-9756497
Enterprise Value?$2.5M
Fundamentals ratios updated end of day